Targeting ryanodine receptor type 2 to mitigate chemotherapy-induced neurocognitive impairments in mice
Editor’s summary Cancer survivors often experience cognitive impairments after chemotherapy, and these side effects are commonly known as chemobrain. Here, Liu and colleagues treated breast